We assessed the pharmacodynamic activity of ertapenem against Escherichia coli with reduced susceptibility (MIC 0.12-0.5 mg/L), intermediate resistance (MIC 1.0 mg/L) or resistance (MIC ≥2 mg/L) to ertapenem using an in vitro model.
Introduction
The emergence and spread of extended-spectrum b-lactamase (ESBL)-producing Escherichia coli in the community, in extendedcare facilities and in hospital settings has been well documented.
1 -3 ESBL-producing E. coli are frequently multidrug resistant (MDR; defined as resistant to third-generation cephalosporins and at least two other unrelated antimicrobial classes). 1 -3 Carbapenems such as doripenem, imipenem/cilastatin, meropenem and ertapenem are recognized as the drugs of choice for seriously ill patients with ESBL E. coli infections. 4 However, ESBL-producing E. coli may demonstrate elevated MICs of carbapenems such as ertapenem, and carbapenem resistance due to KPC and NDM is a concern. 5 -9 Few data are available regarding pharmacodynamic outcomes with ertapenem against MDR ESBL-, KPC-or NDM-producing E. coli with elevated MICs of ertapenem or resistance to ertapenem.
Ertapenem demonstrates broad-spectrum antimicrobial activity against many Gram-positive and Gram-negative aerobes and anaerobes and is resistant to nearly all b-lactamases including ESBLs and AmpCs. 4 Extensive protein binding of ertapenem extends the t1 2 and allows for once-daily dosing. 4 Clinical trials have demonstrated that ertapenem has equivalent efficacy and safety to ceftriaxone and piperacillin/tazobactam against a variety of community-acquired infections. 4 The purpose of this study was to assess the pharmacodynamic activity of ertapenem dosed as either 1 g or 2 g per day against genotypically characterized ESBL-, KPC-or NDM-producing E. coli with elevated MICs of ertapenem or resistance to ertapenem using an in vitro pharmacodynamic model.
Materials and methods

Bacterial strains and culture conditions
The E. coli isolates were obtained from the CANWARD study (www. can-r.ca), a national, ongoing Health Canada-endorsed surveillance study assessing antimicrobial resistance in Canadian hospitals. 2, 3 In the CANWARD study, any E. coli with a ceftriaxone MIC ≥1 mg/L was identified as a putative ESBL producer. 3 Putative ESBL phenotypes were confirmed by the disc diffusion method as described by the CLSI. E. coli ATCC 25922 and Klebsiella pneumoniae ATCC 700603 were the control strains. Genotypic characterization of ESBLs was performed by PCR and the sequencing of bla SHV , bla TEM , bla CTX , bla OXA and bla VEB genes was performed as previously described. 3 A BLAST search of the DNA sequence was conducted to determine the specific ESBL genotype. All putative carbapenemase-producing E. coli and K. pneumoniae were screened for the presence of bla KPC , bla IMP , bla VIM , bla IMI , bla NDM , bla GES and bla OXA-48 by multiplex PCR as described by Denisuik et al. 3 The NDM strain was a generous gift from Dr Johann Pitout (Calgary Laboratory Services, Calgary, Canada). All 15 ESBL, KPC or NDM E. coli strains were chosen because they had elevated MICs of ertapenem ranging from 0.12 mg/L to 256 mg/L as well as being MDR phenotypes. The current CLSI breakpoints for ertapenem and E. coli are: ≤0.5 mg/L, susceptible; 1.0 mg/L, intermediately resistant; and ≥2 mg/L, resistant. Table 1) .
For the pharmacodynamic studies, logarithmic-phase cultures with a turbidity equivalent to that of a 0.5 McFarland standard (1×10 8 cfu/mL) in cation-supplemented Mueller -Hinton broth were prepared as previously described. 5 Viable bacterial counts consistently yielded a starting inoculum of 1×10 6 cfu/mL. A growth control was included in every experiment. Growth controls peaked at 1×10 9 cfu/mL and were maintained over the 48 h experiment.
Antibiotic preparations and susceptibility testing
Antibiotic agents were obtained as laboratory-grade powders from their respective manufacturers (ertapenem was from Merck, Montreal, Quebec). Stock solutions were made according to the CLSI M7-A6 method. MICs were determined by the CLSI-approved broth microdilution method. All MICs were determined in triplicate on separate days. 3, 5 Pharmacokinetics of ertapenem in the in vitro pharmacodynamic model Experiments were performed simulating the C max and AUC 24 of ertapenem, achieved in human serum after standard intravenous doses (1 g of ertapenem once daily) as well as after a 2 g daily dose (Table 1) . 5 Protein-free ( f ) (unbound) serum concentrations were simulated using known protein binding fractions (ertapenem 90%). 4, 5 Ertapenem clearance was simulated using a reported serum t1 2 of 4 h. 5 The pharmacokinetics of ertapenem were evaluated by dosing using standard doses in the central compartment and sampling from this compartment at 0, 1, 2, 4, 6, 12, 18, 24, 36 and 48 h. Ertapenem concentrations were determined in quadruplicate using Bacillus subtilis ATCC 6633 as the test organism with a lower limit of quantification of 0.25 mg/L as previously described. 5 The correlation coefficient of this assay was 0.85. The intra-day and inter-day coefficients of variation were 2.8% -6.0% and 2.4% -5.1%, respectively. The f AUC 24 (mg . h/L) for ertapenem was calculated using the trapezoidal rule. 5 The f AUC 24 /MIC was calculated for ertapenem against the specific E. coli studied.
In vitro pharmacodynamic model/pharmacodynamic experiments
The in vitro pharmacodynamic model used in this study has previously been described. 5 Logarithmic-phase cultures were diluted into fresh cation-supplemented Mueller-Hinton broth to achieve a final inoculum of 1×10 6 cfu/mL. Only free (protein-unbound) serum concentrations were simulated. Pharmacodynamic experiments were performed in duplicate (on separate days) in ambient air at 378C. Sampling was performed at 0, 1, 2, 4, 6, 12, 18, 24, 36 and 48 h as previously described. 5 The lowest dilution plated was 0.1 mL of undiluted sample and the lowest level of detection was 200 cfu/mL (20 colonies of 0.1 mL undiluted sample). Antibiotic carry-over was minimized by diluting samples withdrawn from the model or by repeated washing and centrifugation. No difference in antibiotic carry-over was observed between dilution and washing. Measurement of antibacterial effects was assessed as log 10 changes in bacterial counts at 6, 12, 24 and 48 h with respect to time 0 (the initial inoculum).
Results
All 15 ESBL-or carbapenemase-producing E. coli were genotyped as CTX-M, KPC-3 or NDM-1 and were isolated from the following clinical sites: blood (n ¼ 2), respiratory tract (n ¼ 5), urine (n ¼ 6) and wound (n¼ 2). All strains were MDR. The resistance rates of the 15 MDR E. coli were: 100% (15/15) to ceftriaxone, 100% (15/15) to ciprofloxacin, 60% (9/15) to gentamicin, 67% (10/15) to trimethoprim/sulfamethoxazole and 27% (4/15) to piperacillin/tazobactam. All isolates were susceptible to tigecycline and colistin (polymyxin E). The ertapenem MICs (mg/L) (number of strains, susceptible or resistant) studied were: 0.03 (one, susceptible, wild-type strain), 0.12 (one, susceptible) and 0.25 (one, susceptible), 0.5 (three, susceptible), 1.0 (four, intermediately resistant), 2.0 (three, resistant), 4.0 (one, resistant), 8.0 (one, resistant) and 256 (one, resistant) ( Table 1) .
The simulated and achieved pharmacokinetic profiles of ertapenem in the central compartment of the pharmacodynamic model were within 15% -20% of the simulated pharmacokinetic values. After 1 g daily dosing the achieved ertapenem pharmacokinetics were f C max 13.7+1.7 mg/L (simulated f C max 15.0 mg/L), t1 (Table 1) .
The pharmacodynamic activity of 1 g of ertapenem once daily against MDR ESBL-producing E. coli, simulating free serum concentrations, is displayed in Table 2 . After the 1 g once-daily administration of ertapenem a T .MIC ≥75.4% (ertapenem MICs ≤0.5 mg/L) resulted in bactericidal (≥3 log 10 killing) activity at 6, 12, 24 and 48 h against all tested strains. No significant increase in MIC (≥4-fold) occurred with any strain with an ertapenem MIC ≤0.5 mg/L over the 48 h exposure ( Table 2 ). An ertapenem T .MIC of 61% (ertapenem MICs 1.0 mg/L) resulted in bactericidal (≥3 log 10 killing) activity at 6 and 12 h in all strains but minor regrowth at 24 and 48 h occurred in two strains. In one of the strains with regrowth, the MIC of ertapenem increased from 1 to 2 mg/L. An ertapenem T .MIC of 13% -43% (ertapenem MICs 2 -8 mg/L) resulted in bactericidal (≥3 log 10 killing) activity at 6 h but regrowth (with MIC increases) occurred at 12, 24 and 48 h against all strains. In the five strains with ertapenem MICs of 2 -8 mg/L, regrowth occurred with MIC increases of 2-to 16-fold. After the 2 g once-daily administration of ertapenem, a T .MIC ≥78.0% (ertapenem MICs ≤1.0 mg/L) resulted in bactericidal (≥3 log 10 killing) activity at 6, 12, 24 and 48 h against all tested strains. No significant increase in MIC occurred for any strain with an ertapenem MIC ≤1.0 mg/L over the 48 h exposure (Table 3 ). An ertapenem T .MIC of 61% (ertapenem MICs 2.0 mg/L) resulted in bactericidal (≥3 log 10 killing) activity at 6 and 12 h in all strains but minor regrowth at 24 and 48 h occurred in two strains. 
Discussion
Ertapenem is considered to be the treatment of choice for ESBL-producing E. coli infections including bacteraemia. 10 -14 This is due to carbapenems demonstrating potent in vitro activity against E. coli (99.8% susceptibility for all E. coli and 97.8% susceptibility for ESBL-producing E. coli) 3,7 as well as bacteriological eradication and clinical efficacy. 10 -13 Our in vitro study supports these in vivo data as in this study we showed that ertapenem was rapidly bactericidal against ESBL-producing E. coli (when susceptible to ertapenem, with ertapenem MICs ≤0.5 mg/L) when simulating free drug after 1 g intravenous once-daily dosing. Our study provides new data that ertapenem is rapidly bactericidal in vitro against MDR ESBL-producing E. coli even when intermediately resistant to ertapenem (ertapenem MICs 1.0 mg/L) when simulating free drug after 2 g intravenous once-daily dosing.
In addition, we showed that a 2 g once-daily dose of ertapenem is bactericidal against ESBL-producing E. coli with an ertapenem MIC of 2.0 mg/L (low-level resistance) but that some strains may regrow over time. Even the 2 g once-daily dose of ertapenem provided little to no inhibition of E. coli with an ertapenem MIC ≥4 mg/L.
Although ertapenem is active against the majority of MDR ESBL-producing E. coli, 3, 7 researchers have reported that infections caused by ertapenem-non-susceptible Enterobacteriaceae (E. coli and K. pneumoniae) are associated with greater mortality than infections caused by ertapenem-susceptible Enterobacteriaceae. 8, 9 Our in vitro study supports these in vivo data, as we showed in this study that 1 g of ertapenem once daily against E. coli with an ertapenem MIC of 2 -8 mg/L (resistant ≥2 mg/L) resulted in early bactericidal activity but was followed by regrowth (with increases in the MIC of ertapenem) at 12, 24 and 48 h. In addition, for strains that were intermediately resistant to ertapenem (ertapenem MICs 1.0 mg/L), regrowth (along with increases in MIC) at 24 and 48 h occurred in two strains even though we obtained bactericidal activity at 6 and 12 h in all strains. Our in vitro data are also in agreement with those of Lee et al., 8 who reported increased mortality in patients with bacteraemia due to E. coli and K. pneumoniae for strains that were intermediately resistant to ertapenem.
In our study, we initially simulated ertapenem dosing using the recommended dosing for the treatment of community-acquired infections, which is 1 g (intravenously) once daily. 4 This dose has been reported to result in not only high tissue penetration in patients with infectious diseases, but also high bacteriological eradication and clinical success. 4, 15 However, we then simulated 2 g of ertapenem once daily as this dose has been used clinically. 15 Ferry et al. 16 reported a clinical success rate of 93% when using 2 g of ertapenem per day (intravenously or subcutaneously) in patients with difficult-to-treat bone and joint infections. Many of the 17 patients treated were infected with MDR Enterobacteriaceae. Reported C max values ranged from 36.8 to 136.6 mg/L (average 86.2 mg/L). 16 Ertapenem at a dosage of 2 g per day was both Pharmacodynamics of ertapenem versus ESBL, KPC or NDM E. coli efficacious and safe, even with a prolonged duration of therapy (range 14 -203 days in total). Our in vitro study demonstrated that 2 g of ertapenem per day was able to eradicate MDR ESBL-producing E. coli with elevated MICs of ertapenem (ertapenem MICs 0.5 mg/L) and intermediately resistant to ertapenem (ertapenem MICs 1.0 mg/L) and also provided initial bactericidal activity against strains with low-level resistance (ertapenem MICs 2.0 mg/L), although regrowth occurred over time. Thus, as the pathogens adapt to our therapies and become less susceptible, we need to consider adapting our antimicrobial dosing regimens to optimize bacterial eradication. An important limitation of this study is that we simulated ertapenem pharmacokinetics obtained from healthy individuals. 4 Pharmacokinetic parameters obtained from healthy individuals may not necessary reflect pharmacokinetics in patients with disease states. In addition, it has been suggested that the protein binding of ertapenem may decrease with higher (i.e. 2 g) ertapenem dosing. 4 We chose to be conservative and model higher protein binding, thus simulating lower free drug levels.
We conclude that once-daily dosing with 1 g of ertapenem was bactericidal against ESBL-producing E. coli (ertapenem MICs ≤0.5 mg/L) at all timepoints and was bactericidal versus strains with MICs of 1.0 mg/L although regrowth occurred in some strains; for strains with ertapenem MICs of 2-8 mg/L, early bactericidal activity was followed by regrowth at all timepoints. A dosage of 2 g of ertapenem once daily proved to be bactericidal at all timepoints against strains with MICs of 1.0 mg/L, but regrowth occurred in some strains with ertapenem MICs of 2 mg/L. Ertapenem provided no inhibition of NDM-producing E. coli.
